Clinical Trial: Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Castration-Resistant Prostate Carcinoma
Study Type: INTERVENTIONAL
Official Title: Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
Brief Summary:
This phase II trial studies how well prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans (in combination with bone scans) work in selecting patients for Ra-223 radiation therapy that have castration-resistant prostate cancer that has spread from where it first started (primary site) to the bones (bone metastasis).Ra-223 is a type of therapy that emits radiation.Radiation gives off energy which can kill tumor cells and other cells that may support the tumor cells.Ra-223 is given by…
Read more